These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 27362616)

  • 1. G-Protein-Coupled Receptor Kinase 2 (GRK2) Inhibitors: Current Trends and Future Perspectives.
    Guccione M; Ettari R; Taliani S; Da Settimo F; Zappalà M; Grasso S
    J Med Chem; 2016 Oct; 59(20):9277-9294. PubMed ID: 27362616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utilizing a structure-based docking approach to develop potent G protein-coupled receptor kinase (GRK) 2 and 5 inhibitors.
    Waldschmidt HV; Bouley R; Kirchhoff PD; Lee P; Tesmer JJG; Larsen SD
    Bioorg Med Chem Lett; 2018 May; 28(9):1507-1515. PubMed ID: 29627263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of inhibitors of the RGS homology domain of GRK2 by docking-based virtual screening.
    Echeverría E; Velez Rueda AJ; Cabrera M; Juritz E; Burghi V; Fabián L; Davio C; Lorenzano Menna P; Fernández NC
    Life Sci; 2019 Dec; 239():116872. PubMed ID: 31525427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and efficacy of novel G protein-coupled receptor kinase 2 inhibitors.
    Carotenuto A; Cipolletta E; Gomez-Monterrey I; Sala M; Vernieri E; Limatola A; Bertamino A; Musella S; Sorriento D; Grieco P; Trimarco B; Novellino E; Iaccarino G; Campiglia P
    Eur J Med Chem; 2013 Nov; 69():384-92. PubMed ID: 24077529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of Inflammatory Immune Response-Related Drugs Based on G Protein-Coupled Receptor Kinase 2.
    Han C; Li Y; Wang Y; Cui D; Luo T; Zhang Y; Ma Y; Wei W
    Cell Physiol Biochem; 2018; 51(2):729-745. PubMed ID: 30463058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hit-to-lead optimization and discovery of a potent, and orally bioavailable G protein coupled receptor kinase 2 (GRK2) inhibitor.
    Xu G; Gaul MD; Liu Z; DesJarlais RL; Qi J; Wang W; Krosky D; Petrounia I; Milligan CM; Hermans A; Lu HR; Huang DZ; Xu JZ; Spurlino JC
    Bioorg Med Chem Lett; 2020 Dec; 30(23):127602. PubMed ID: 33038544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Computational study of paroxetine-like inhibitors reveals new molecular insight to inhibit GRK2 with selectivity over ROCK1.
    Keretsu S; Bhujbal SP; Joo Cho S
    Sci Rep; 2019 Sep; 9(1):13053. PubMed ID: 31506468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, Synthesis, and Evaluation of the Highly Selective and Potent G-Protein-Coupled Receptor Kinase 2 (GRK2) Inhibitor for the Potential Treatment of Heart Failure.
    Okawa T; Aramaki Y; Yamamoto M; Kobayashi T; Fukumoto S; Toyoda Y; Henta T; Hata A; Ikeda S; Kaneko M; Hoffman ID; Sang BC; Zou H; Kawamoto T
    J Med Chem; 2017 Aug; 60(16):6942-6990. PubMed ID: 28699740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular mechanism of selectivity among G protein-coupled receptor kinase 2 inhibitors.
    Thal DM; Yeow RY; Schoenau C; Huber J; Tesmer JJ
    Mol Pharmacol; 2011 Aug; 80(2):294-303. PubMed ID: 21596927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design of substrates and inhibitors of G protein-coupled receptor kinase 2 (GRK2) based on its phosphorylation reaction.
    Kang JH; Toita R; Kawano T; Murata M; Asai D
    Amino Acids; 2020 Jul; 52(6-7):863-870. PubMed ID: 32577910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-Based Design of Highly Selective and Potent G Protein-Coupled Receptor Kinase 2 Inhibitors Based on Paroxetine.
    Waldschmidt HV; Homan KT; Cato MC; Cruz-Rodríguez O; Cannavo A; Wilson MW; Song J; Cheung JY; Koch WJ; Tesmer JJ; Larsen SD
    J Med Chem; 2017 Apr; 60(7):3052-3069. PubMed ID: 28323425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrating GRK2 and NFkappaB in the Pathophysiology of Cardiac Hypertrophy.
    Sorriento D; Santulli G; Franco A; Cipolletta E; Napolitano L; Gambardella J; Gomez-Monterrey I; Campiglia P; Trimarco B; Iaccarino G; Ciccarelli M
    J Cardiovasc Transl Res; 2015 Nov; 8(8):493-502. PubMed ID: 26224342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tonic inhibition by G protein-coupled receptor kinase 2 of Akt/endothelial nitric-oxide synthase signaling in human vascular endothelial cells under conditions of hyperglycemia with high insulin levels.
    Taguchi K; Sakata K; Ohashi W; Imaizumi T; Imura J; Hattori Y
    J Pharmacol Exp Ther; 2014 May; 349(2):199-208. PubMed ID: 24570070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Downregulation of G protein-coupled receptor kinase 2 levels enhances cardiac insulin sensitivity and switches on cardioprotective gene expression patterns.
    Lucas E; Jurado-Pueyo M; Fortuño MA; Fernández-Veledo S; Vila-Bedmar R; Jiménez-Borreguero LJ; Lazcano JJ; Gao E; Gómez-Ambrosi J; Frühbeck G; Koch WJ; Díez J; Mayor F; Murga C
    Biochim Biophys Acta; 2014 Dec; 1842(12 Pt A):2448-56. PubMed ID: 25239306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulatory effects of GRK2 on GPCRs and non-GPCRs and possible use as a drug target (Review).
    Han CC; Ma Y; Li Y; Wang Y; Wei W
    Int J Mol Med; 2016 Oct; 38(4):987-94. PubMed ID: 27573285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GRK2 and GRK5 as therapeutic targets and their role in maladaptive and pathological cardiac hypertrophy.
    Lieu M; Koch WJ
    Expert Opin Ther Targets; 2019 Mar; 23(3):201-214. PubMed ID: 30701991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selectivity mechanism of GRK2/5 inhibition through in silico investigation.
    Wu Y; Wang S; Wang H; Hu B; Wang J
    Comput Biol Chem; 2022 Dec; 101():107786. PubMed ID: 36399961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antidiabetic and Cardioprotective Effects of Pharmacological Inhibition of GRK2 in db/db Mice.
    Cipolletta E; Gambardella J; Fiordelisi A; Del Giudice C; Di Vaia E; Ciccarelli M; Sala M; Campiglia P; Coscioni E; Trimarco B; Sorriento D; Iaccarino G
    Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30934608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GRK2 as negative modulator of NO bioavailability: Implications for cardiovascular disease.
    Cannavo A; Koch WJ
    Cell Signal; 2018 Jan; 41():33-40. PubMed ID: 28077324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. G protein-coupled receptor kinase 2 (GRK2) as an integrative signalling node in the regulation of cardiovascular function and metabolic homeostasis.
    Mayor F; Cruces-Sande M; Arcones AC; Vila-Bedmar R; Briones AM; Salaices M; Murga C
    Cell Signal; 2018 Jan; 41():25-32. PubMed ID: 28389415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.